Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ciprofloxacin + tinidazole is a fixed-dose combination of two antimicrobial agents used to treat a broad range of bacterial and protozoal infections. Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and repair in bacteria, leading to cell death. Tinidazole is a nitroimidazole derivative with antiprotozoal and antibacterial activity; it works by damaging the DNA of anaerobic bacteria and protozoa, preventing their growth and multiplication. This combination is commonly prescribed for gastrointestinal infections (including traveler’s diarrhea), gynecological infections, certain sexually transmitted diseases (such as trichomoniasis), amebiasis, giardiasis, as well as for prophylaxis after surgery[1][2][4][5]. It has also been studied in chronic refractory pouchitis[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ciprofloxacin + tinidazole.